Loading...
The Angiogenic effect of Erythropoietin on Stem Cells In-Vitro
Milewski, Michael Edward
Milewski, Michael Edward
Citations
Altmetric:
Genre
Thesis/Dissertation
Date
2011
Advisor
Committee member
Group
Department
Biology
Permanent link to this record
Collections
Research Projects
Organizational Units
Journal Issue
DOI
http://dx.doi.org/10.34944/dspace/1904
Abstract
Angiogenesis is a normal and vital process that occurs during growth and development. Repair of bony defects, whether in the craniofacial complex or the alveolus, require an alloplastic or xenoplastic bone graft with angiogenic potential. This angiogenic potential is derived from existing blood vessels adjacent to the graft site. Improving the endogenous angiogenic potential with a molecule would drastically improve the survival rate of the bone graft material. This study was conducted to test the hypothesis that specific stem cell lines treated with erythropoietin, a positive promoter of angiogenesis, may increase the erythropoietin receptor expression in-vitro. In addition, this study also evaluated the vascular branching in vitro of human umbilical vein-derived endothelial cells treated with erythropoietin in the matrigel assay. Human umbilical vein-derived endothelial cells were treated for seven days with four concentrations of erythropoietin and cellular branching was evaluated in the matrigel assay. human bone marrow-derived mesenchymal stem cells and multi-potent cord blood derived unrestricted stromal stem cells were treated for seven days with erythropoietin and erythropoietin receptor expression was evaluated via reverse transcriptase real time polymerase chain reaction and real time polymerase chain reaction assays. The results of this study indicate that: erythropoietin had no effect on human umbilical vein-derived endothelial cells in the matrigel assay from a qualitative perspective, after treating multi-potent cord blood derived unrestricted stromal stem cells cells for 7 days with erythropoietin, there was no statistically significant difference between treatment groups when compared to control, and after treating human bone marrow-derived mesenchymal stem cells cells for 7 days with erythropoietin, the 20 U/ml treatment group showed a statistically significant reduction of the erythropoietin receptor as compared to the control group.
Description
Citation
Citation to related work
Has part
ADA compliance
For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu